Daniel Lachant, ATS 2022: Transitioning from Selexipag to Oral Treprostinil in PAH
touchRESPIRATORY caught up with Dr. Daniel Lachant (University of Rochester Medical Center, Rochester, NY, USA) around his analysis of the ADAPT Registry, investigating the transition from selexipag to oral treprostinil in patients with pulmonary arterial hypertension.
The abstract ‘Clinical Improvement in Pulmonary Arterial Hypertension (PAH) Patients Transitioning from Selexipag to Oral Treprostinil: Interim Results from the ADAPT Registry.’ (Abstract number: 608) was presented at ATS 2022, 13-18 May 2022.
- Since its approval, what has been the impact of treprostinil on the treatment paradigm for pulmonary arterial hypertension (PAH)? (0:36)
- What are the treatment goals in PAH and why has clinical improvement been a recent focus? (1:55)
- Could you tell us a little about the ADAPT registry and the aims of the current analysis? (2:56)
- What were the findings in patients who transitioned from selexipag to treprostinil? (3:58)
- What do you think are the reasons for this improvement after transitioning? (6:44)
Disclosures: Daniel Lachant discloses consulting for, receiving grant/ research support from, serving on advisory boards and speaker’s bureaus for United Therapeutics.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ATS meeting 2022.
Share this Video
Related Videos In Pulmonary Hypertension
Jean Elwing, CHEST 2022: Inhaled treprostinil for pulmonary hypertension due to interstitial lung disease – the INCREASE OLE study
INCREASE OLE was the open-label extension of the INCREASE study (NCT02630316), which investigated the safety and efficacy of inhaled treprostinil in patients with pulmonary hypertension due to interstitial lung disease. We caught up with Prof. Jean Elwing (UC Health, Cincinnati, OH, USA) to discuss the methodology, inclusion criteria, and safety and tolerability findings from the […]
Marc Simon, CHEST 2022: Clinical benefits with a higher dose of LIQ861 in pulmonary arterial hypertension – analysis of the LTI-301 clinical trial
INSPIRE (LTI-301 clinical trial) was a phase 3 study investigating the long-term safety and tolerability of LIQ861 in patients with pulmonary arterial hypertension (NCT03399604). touchRESPIRATORY were delighted to talk with Dr. Marc Simon (UCSF Health, San Francisco, CA, USA) around the aims, design and eligibility criteria of the LTI-301 clinical trial and the findings from […]
Marc Simon, CHEST 2022: LIQ861 for the treatment of pulmonary arterial hypertension
LIQ861 is an investigational, inhaled dry powder formulation of treprostinil delivered through a device, which currently has tentative approval from the FDA for the treatment of pulmonary arterial hypertension (PAH). touchRESPIRATORY were delighted to talk with Dr. Marc Simon (UCSF Health, San Francisco, CA, USA) about LIQ861 and its potential advantages over conventional formulations of […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!